ABSTRACT
The testosterone matrix patch is currently in phase III clinical trials in postmenopausal women. To date the investigational matrix patches have been well tolerated and local androgenic effects on the skin have not been reported. Providing that circulating androgen concentrations are kept within or close to the upper limit of the normal physiologic range, masculinizing effects are extremely unlikely.7 The major side effect encountered has been allergy to the patch adhesive with an erythematous reaction at the patch site.7 The site reaction is usually mild and can be minimized by rotating the patch site on each application. However, evidence of systemic sensitization requires discontinuation of therapy.
